Published Medical Literature

Survivors of Gynecologic Cancers Favor Routine Sexual Health Counseling

Study Identifies Prognostic Factors in Malignant Adult Ovarian Germ Cell Tumors

KIF26B Expression Linked to Paclitaxel Resistance and Prognosis in Ovarian Cancer

Rucaparib Maintenance Demonstrates Durable 5-Year Benefit in Ovarian Cancer

Ovarian Cancer Risk Varies by Reproductive Factors, Menopause, and Birth Cohort

ESGO Consensus: Opportunistic Salpingectomy for Preventing Tubo-Ovarian Carcinoma

Use of CGP Expands Potential for Precision Medicine in High-Grade Serous Ovarian Cancer

EGFR Mutations in Ovarian Cancer: Rare but Actionable Targets

Avutometinib and Defactinib Combination Leads to Durable Responses in Recurrent Low-Grade Serous Ovarian Cancer

Impact of Neoadjuvant Chemotherapy and Hospital Volume on Mortality in Ovarian Cancer

Could Paclitaxel-Based HIPEC Be an Alternative to Cisplatin-Based HIPEC Following Interval Cytoreduction for Advanced Ovarian Cancer?

PPP2R1A Mutations Signal Improved Survival Outcomes Following Immunotherapy in Ovarian Clear Cell Carcinoma

Role of NRF2 in High-Grade Serous Ovarian Cancer

Relacorilant Added to Nab-Paclitaxel Benefits Patients With Platinum-Resistant Ovarian Cancer

Quantifying the Global Socioeconomic Burden of Ovarian Cancer

Is Pembrolizumab Monotherapy of Benefit in Previously Treated Advanced Clear Cell Gynecologic Cancer?

Final Results From ARIEL4: Rucaparib vs Chemotherapy for BRCA-Mutated Ovarian Cancer

Can C-reactive Protein and Serum Albumin Levels Help Determine Ovarian Cancer Severity?

Oncogene UBE2J1 Tied to High-Grade Serous Ovarian Cancer

Link Between Elevated Inflammatory Marker and Aggressive Ovarian Cancer Phenotypes?

Genetic Testing in Gynecologic Cancers: Breaking Barriers for Better Patient Care

Can LOC730101 Improve Drug Sensitivity in Ovarian Cancer Treatment?

Can Flutamide-Induced Restoration of miRNA-449 Reduce the Risk of Ovarian Cancer?

Opportunistic Salpingectomy: A Potential Preventive Tool in Ovarian Cancer?

Serous Epithelial Ovarian Cancer: Investigating the Role of Plakins in Metastasis

Efficacy of T-DXd in HER2-Expressing Gynecologic Malignancies: Real-World Data

Do Ovarian Tumor Cells Sabotage Nearby Cells Using Long Noncoding RNA?

Adding HIPEC to Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer

Can HIPEC Plus Cytoreductive Therapy Improve Outcomes in Recurrent Ovarian Cancer?

Predicting Prognosis in HGSOC: Focus on Myeloid-Driven T-Cell Exhaustion

Advanced Ovarian Cancer: IV vs IP Chemotherapy With or Without Bevacizumab

Trends in Upfront Surgical Treatment in Advanced Ovarian Cancer: Where Does Neoadjuvant Chemotherapy Fit?

Does Risk-Reducing Salpingo-Oophorectomy Increase Long-Term Cardiovascular Risk?

Can Intraperitoneal Ropivacaine Accelerate Recovery From Advanced Ovarian Cancer Surgery?

Targeting Immune Cell Molecules May Improve Chemotherapy Response in HGSOC

Evaluating the Clinical Utility of FRα as a Therapeutic Target in Ovarian Cancer

Germline Genetic Testing for Breast and Ovarian Cancer Risk in the United Arab Emirates

Long-Term Effects of PARP Inhibitors in HRD-Positive Ovarian Cancer

Researchers Share Unexpected Finding in Development of New Model for Ovarian Cancer

Chemotherapy Before or After Surgery in Advanced Ovarian Cancer: Comparing Outcomes

Individualized Niraparib Dosing for Platinum-Sensitive Recurrent Ovarian Cancer

Does IgA Affect Antitumor Activity of Immune Cells in Ovarian Cancer?

WEE1 Inhibitor Adavosertib Plus Gemcitabine in High-Grade Serous Ovarian Cancer

Gemogenovatucel-T Immunotherapy for Ovarian Cancer Maintenance

Prospective Pilot Study: Streamlining Genetic Testing for Newly Diagnosed Ovarian Cancer

Does Assisted Reproductive Technology Increase the Risk for Ovarian Carcinoma?

Identifying Gene Mutations in Patients With High-Grade Serious Ovarian Carcinoma

Role of Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer

Case Study: Olaparib Maintenance for High-Grade Serous Ovarian Cancer With Brain Metastases

Chemotherapy-Induced Changes to the Tumor Microenvironment and Outcomes in Ovarian Cancer

Oncologist-Initiated Genetic Testing Versus Genetics Referral for Ovarian Cancer Subtype

Combination ATR and PARP Inhibition Under Study in Relapsed Ovarian Cancer

Primary Treatment and Survival in Advanced-Stage Epithelial Ovarian Cancer: U.S. Trends

Are There Racial Differences in Germ Cell and Sex Cord Stromal Ovarian Tumors?

Surveillance Patterns After Treatment for Primary Epithelial Ovarian Cancer

Nutritional Status of Patients With Ovarian Cancer: Carotenoids and Fat-Soluble Vitamins

Advanced Ovarian Cancer: Does Adding HIPEC to Cytoreductive Surgery Improve Outcomes?

First‐Line Treatment of Ovarian Cancer: Weekly Carboplatin/Paclitaxel Versus Standard Regimen

Bevacizumab-Induced Arthralgia in Patients With Advanced Ovarian Cancer

Intrathoracic Disease and Advanced Ovarian Cancer: Focus on Video-Assisted Surgery

Rucaparib Maintenance for Recurrent Ovarian Carcinoma: Update From ARIEL3

Integrin Inhibitor Under Study as Targeted Therapy for Ovarian Cancer

Maintenance Olaparib for Ovarian Cancer: Subgroup Analysis From SOLO1 Trial

Social Media Survey: How COVID-19 Is Affecting Gynecologic Oncology Practice

Differences in Race/Ethnicity and Survival Outcomes in Epithelial Ovarian Cancer

Saving Fertility: Success After Surgery for Borderline Ovarian Tumors?

Comparison of Chemotherapy Regimens for Newly Diagnosed Ovarian Cancer

Are Papanicolaou Tests Useful in Diagnosing Ovarian Cancer?

Use of Apatinib in Platinum-Resistant Epithelial Ovarian Cancer

Secondary Cytoreductive Surgery Plus Niraparib for Recurrent Ovarian Cancer Under Study

Novel Antibody-Drug Conjugate Under Study in Platinum-Sensitive Ovarian Cancer

Combination Therapy of Vaccine and Durvalumab in Advanced Ovarian Cancer

SGO Clinical Practice Statement on Hormone Therapy for Certain Gynecologic Cancers

Phase II EVOLVE Trial: Genomic Mechanisms of Resistance to PARP Inhibitors

Consequences of Frequent Imaging in Recurrent Advanced Ovarian Cancer

Olaparib Treatment for Platinum-Sensitive Relapsed Ovarian Cancer: SOLO3 Trial

ARIEL3 Trial Update on Rucaparib Maintenance for Recurrent Ovarian Cancer

Feasibility of Reducing One Cycle of Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

COVID-19 and Ovarian Cancer: Shared Experiences From Japan and Korea

Study Finds Disney Films Offer Surprising Benefits for Women Treated for Gynecologic Cancer

Head-to-Head Trial Compares Bevacizumab/Platinum-Based Regimens in Recurrent Ovarian Cancer

Is Endosalpingiosis Associated With Higher Rates of Ovarian Cancer?

Complications After Primary Cytoreduction for Advanced Ovarian Cancer

Identifying Molecular Mechanisms Driving Ovarian Cancer

Biomarkers May Predict Sensitivity to Combined PARP and PD-1 Inhibition in Ovarian Cancer

Gemcitabine Plus Bevacizumab for Platinum-Resistant Gynecologic Cancers

Can Breastfeeding Reduce the Risk for Ovarian Cancer?

Diagnostic Panel for Ovarian Mucinous Neoplasms

Characterization of Exosomes From Ovarian Cancer and Ovarian Epithelial Cells

Genetic Change May Distinguish Rare Benign Ovarian Tumors From Cancerous Tumors

Cyclophilin A: Potential Therapeutic Target in Serous Ovarian Cancer?

Can Cervical Scrapings From Pap Tests Detect Ovarian Cancer?

Maintenance Olaparib in Advanced Ovarian Cancer: PAOLA-1 Trial

Two Prediction Models Evaluate CA125 and Ovarian Cancer Risk

Everolimus Plus Bevacizumab in Recurrent Ovarian Cancer

Heat Shock Protein 90: Key Player in New Ovarian Cancer Research

Weekly Dose-Dense Paclitaxel in Ovarian Cancer: ICON8 Trial

Niraparib in Newly Diagnosed Advanced Ovarian Cancer

How Does Secondary Surgical Cytoreduction Compare With Chemotherapy for Recurrent Ovarian Cancer?

Olaparib Plus Durvalumab Treatment of BRCA-Mutant Ovarian Cancer: MEDIOLA Trial

Can Metformin Play a Role in Preventing Ovarian Cancer?

Adding Vistusertib to Paclitaxel in Platinum-Resistant Ovarian Cancer

New Imaging Method May Improve Accuracy of Classifying Peritoneal Metastases

Ovarian Cancer Exosomes Promote Niche Formation for Metastatic Growth

VELIA/GOG-3005 Trial Update on PARP Inhibitor in Ovarian Cancer

Do Intrauterine Devices Offer Benefits Beyond Contraception?

Researchers Identify Molecular Origin of Mucinous Ovarian Carcinoma

Niraparib Maintenance Versus Surveillance in Recurrent Ovarian Cancer

Posttraumatic Stress Disorder Linked to Higher Risk of Ovarian Cancer, Study Finds

Pamiparib Plus Tislelizumab Being Studied Further in Ovarian Cancer

Linking Ovarian Cancer and Cervicovaginal Microbiota

Niraparib Plus Pembrolizumab in Recurrent Platinum-Resistant Ovarian Carcinoma

Bevacizumab for Ovarian Cancer: Final Overall Survival Analysis of GOG-0218

Role of BRCA Mutation in Hypersensitivity Reactions to Chemotherapy in Ovarian Cancer

Is Adding Entinostat to Avelumab of Benefit in Treating Advanced Epithelial Ovarian Cancer?

Link Between Folate Deficiency and Olaparib Treatment in Ovarian Cancer: Case Reports

ENGOT-OV16/NOVA Trial: Niraparib Maintenance for Recurrent Ovarian Cancer

Long Noncoding RNAs in a Risk Score System for Ovarian Cancer

Ribociclib and Letrozole Combination Therapy for Ovarian and Endometrial Cancers

Targeting Ovarian Cancer With Combination of PARP Inhibitors and Senolytic Agents

Intensity-Modulated Radiotherapy and Preservation of Ovarian Function

Role of Activated Endothelial Cells in Recurrent Ovarian Cancer

Phase III Trial Results of Trebananib Combination Therapy in Ovarian Cancer

Genetic Testing for Patients With Ovarian Cancers: Can Counseling Improve Decision-Making?

Might Circulating Tumor DNA Guide Clinical Decisions in Aggressive Ovarian Cancer?

IV Versus IP Chemotherapy Plus Bevacizumab in Advanced Ovarian Cancer

Long-Term Fatigue Among Survivors of Epithelial Ovarian Cancer

QUADRA Trial: Niraparib Active in Late-Line Ovarian Cancer

Novel Microscopic Imaging System for Ovarian Tumor Surgery

AACR Special Conference: Questions to Be Answered in Ovarian Cancer Research and Treatment

Genetic Testing in Ovarian and Breast Cancer

Improving Detection of Ovarian Cancer With the CA125 Biomarker

Is Female Infertility Associated With a Higher Risk of Cancer?

Treatment With Avelumab in Resistant Ovarian Cancer

Cediranib Plus Olaparib in Relapsed Platinum-Sensitive Ovarian Cancer

Ovarian Carcinosarcoma: Update on a Rare Malignancy

Risk of Ovarian Cancer After Radical Cystectomy for Bladder Cancer

Conservative Management Approach to Benign Ovarian Cysts and Risk of Complications

Tisotumab Vedotin Exhibits Antitumor Activity in Ovarian Cancer, Among Other Cancers

Atypical Histologic Type of Ovarian Cancer and Cowden Syndrome

Costs of Surgical Care for Women With Ovarian Cancer

Using Artificial Intelligence Tool to Identify Aggressive Ovarian Cancer Cells

Maintenance Olaparib in Newly Diagnosed Advanced Ovarian Cancer

International Surveys Focus on Surgical Practice Patterns in Advanced Ovarian Cancer

PALB2 Mutation in Hereditary Breast and Ovarian Cancer

Association Between Risk of Ovarian Cancer and Ultrasonography Findings

Comparing Neoadjuvant Chemotherapy and Debulking Surgery in Advanced Tubo-Ovarian Cancers

Chemosensitivity Mediator and Immunotherapy Target Identified in Ovarian Cancer

Preclinical Study Finds HDAC Inhibitor’s Effect Tied to Immunity Status

Impact of Low-Dose Aspirin Use on Risk of Ovarian Cancer

Can Patient-Derived Ovarian Cancer Organoids Aid in Treatment Selection?

Investigating Resistance to EZH2 Inhibition in ARID1A-Mutated Ovarian Cancer Cells

Population-Level Genomic Screening for Hereditary Ovarian Cancer

Epidural Anesthesia During Primary Debulking Surgery for Advanced Ovarian Cancer

Can Ketogenic Diet Benefit Women With Gynecologic Cancer?

Do Oral Contraceptives Reduce the Risk of Ovarian Cancer?

Consensus Classifier Algorithm Developed to Aid in Tumor Subtype Identification

Alternative to Paclitaxel Under Study in Ovarian and Uterine Cancers

Niraparib Maintenance for Recurrent Ovarian Cancer: Quality-of-Life Results

Does Adding Sorafenib to Topotecan Improve Survival in Platinum-Resistant Ovarian Cancer?

Impact of Olaparib Maintenance Therapy on Outcomes in Ovarian Cancer

Early Serous Proliferations in Fallopian Tube and Advanced High-Grade Ovarian Cancer

Can Use of Analgesics Improve Survival in Women With Ovarian Cancer?

Tumor Treating Fields Combined With Paclitaxel: Safety Results From Pilot Study

Association Between Analgesic Use and Risk of Ovarian Cancer

Parameters for Dose Reduction in Niraparib Therapy for Ovarian Cancer

Novel Antibody-Drug Conjugate in Platinum-Resistant Ovarian Cancer

Does Hormone Replacement Therapy After Oophorectomy Affect Breast Cancer Risk in BRCA1-Mutation Carriers?

Disparities in Genetic Testing for Hereditary Ovarian Cancer in the United States

Patient-Centered Website Focuses on Psychosocial Issues in Patients With Ovarian Cancer

ESMO Clinical Practice Guidelines for Nonepithelial Ovarian Cancer

Does Modified IP Chemotherapy Regimen Improve Tolerability in Patients With Ovarian Cancer?

Novel Counseling Model for Genetic Testing in Patients With Ovarian Cancer

Tumor Grade and Rate of Lymph Node Metastasis in Early-Stage Ovarian Cancer

Secondary Cytoreductive Surgery for Platinum-Sensitive Epithelial Ovarian Cancer

Genetic Biomarker as Potential Predictor of Platinum Sensitivity in Serous Ovarian Tumors

Pilot Clinical Trial of Dendritic Cell Vaccination in Ovarian Cancer

Molecular Subsets of High-Grade Serous Ovarian Tumors May Impact Future Treatments

Do Some Women Inherit Ovarian Cancer From Their Fathers?

Identifying New Clinical Trial Endpoints in the Treatment of Ovarian Cancer

Familial Link Between Testicular Cancer in Men and Ovarian Cancer in Female Relatives

Population-Based Analysis of Fallopian Tube Carcinoma Rates

Prognostic Significance of Genomic Rearrangement Patterns in High-Grade Serous Ovarian Cancer

Impact of Intraperitoneal Chemotherapy on Survival in Advanced Ovarian Cancer

Paclitaxel Plus Pazopanib in Recurrent Ovarian Cancer

Rucaparib Maintenance Therapy for Platinum-Sensitive Ovarian Cancer

Does Small Cell Ovarian Cancer Respond to Immunotherapy?

Managing Toxicities With Niraparib in Maintenance Therapy for Ovarian Cancer